ATOR-1017 (evunzekibart), an Fc-gamma Receptor Conditional 4-1BB Agonist Designed for Optimal Safety and Efficacy, Activates Exhausted T Cells in Combination with Anti-Pd-1.
CANCER IMMUNOLOGY IMMUNOTHERAPY（2023）
关键词
4-1BB,CD137,PD-1,Immunotherapy,Antibody,T cell activation
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要